KYMR
Kymera Therapeutics Inc

715
Loading...
Loading...
News
all
press releases
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Zacks·1mo ago
News Placeholder
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
Zacks·2mo ago
News Placeholder
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·2mo ago
News Placeholder
Kymera’s partnerships with Sanofi and Gilead drive value
Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. 
investing.com·3mo ago
News Placeholder
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Zacks·3mo ago
News Placeholder
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.
Stocktwits·3mo ago
News Placeholder
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Zacks·3mo ago

Latest KYMR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.